Share Twitter LinkedIn Facebook Email Primo N. Lara, Jr., MD, explains whether the TKIs used in the treatment of renal cell carcinoma (RCC) are interchangeable and which TKIs seem to be the most successful in 1st line renal cell carcinoma (RCC)
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC Kidney 4 Mins Read
Nivolumab Combo Phase 3 TiNivo 2 Results + Tivozanib in RCC Presented at ESMO 2024: AVEO Kidney 4 Mins Read
Impact of Latino Ethnicity on Gut Microbiome in mRCC: ASCO 2024 Study – Regina Barragan-Carillo, Phd – City of Hope ASCO Annual Meeting 2 Mins Read
